Blockchain Registration Transaction Record

GeoVax's Mpox Vaccine Gets EMA Green Light for Streamlined Approval Path

GeoVax receives EMA support for GEO-MVA vaccine, streamlining approval for Mpox and smallpox prevention, marking a leap in global health resilience.

The positive feedback from the EMA on GeoVax's GEO-MVA vaccine represents a significant advancement in the fight against Mpox and smallpox, diseases that have been declared a global health emergency. This development not only accelerates the potential approval of a much-needed additional vaccine source but also strengthens global health resilience by diversifying vaccine supply. With the emergence of highly virulent Mpox strains and the ongoing risk of geographical expansion, the availability of GEO-MVA could play a crucial role in preventing further outbreaks and ensuring public health safety worldwide.